ReviewFrontiers in aging2026
Therapeutic potential of stem cell-derived extracellular vesicles in aging and regeneration.
Review in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Role and Mechanism of Endothelial Progenitor Cell-Derived Extracellular Vesicles in Vascular Repair of Ischemic Heart Disease.Journal of cardiovascular translational research · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is characterized by measurable reductions in tissue repair, immune balance, and metabolic regulation. Increasing evidence suggests that these changes may arise, in part, from an insufficiency or altered quality of endogenous extracellular vesicle (EV) signaling. EVs, including exosomes, carry regenerative and immunoregulatory cues, and age-related alterations in their abundance, cargo, and bioactivity have been linked to impaired cellular communication across organ systems. This has fueled growing interest in stem cell-derived EVs, which provide biologically more youthful vesicles that reproduce key paracrine functions of their parent cells while avoiding the limitations of cell transplantation. By transferring defined protein, lipid, and RNA cargoes, these vesicles influence pathways central to aging biology, including mitochondrial function, inflammatory control, and maintenance of stem cell niches. Preclinical studies support their efficacy in models of neurodegeneration, wound healing, musculoskeletal decline, and systemic inflammation. However, their function depends on stem cell origin, donor age, and environmental conditioning, variables that complicate standardization and clinical scalability. As interest expands across therapeutic and cosmetic domains, a comparative understanding of EV sources and their mechanistic actions is required. In this review, we examine stem cell-derived EVs across biological sources, outline how aging and environmental factors shape their regenerative potency, and evaluate current progress in clinical translation. The field has reached a point where future advances depend less on further demonstrations of efficacy and more on resolving challenges related to manufacturing, quality control, and regulatory alignment. Addressing these constraints will determine whether stem cell-derived EVs can progress from experimental promise to practical interventions for aging and regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.